Context Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024Proactive Investors • 11/10/23
Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsGlobeNewsWire • 11/09/23
Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatmentProactive Investors • 10/31/23
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewsWire • 09/27/23
Context Therapeutic says it has enough cash to fund operation into late 2024Proactive Investors • 08/10/23
Context Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsGlobeNewsWire • 08/09/23
Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024Proactive Investors • 05/11/23
Context Therapeutics Reports First Quarter 2023 Operating and Financial ResultsGlobeNewsWire • 05/10/23
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A DifferenceAccesswire • 04/18/23
Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinarProactive Investors • 04/16/23
Context Therapeutics announces pipeline update with FY 2022 financial resultsProactive Investors • 03/23/23
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesGlobeNewsWire • 03/22/23
Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meetingProactive Investors • 03/15/23
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023GlobeNewsWire • 03/15/23
Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancerProactive Investors • 02/06/23
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerGlobeNewsWire • 02/06/23
Context Therapeutics says clinical partner Stemline Therapeutics receives FDA approval for ORSERDU to treat certain breast cancersProactive Investors • 01/31/23
Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast CancerGlobeNewsWire • 01/31/23
Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancersProactive Investors • 01/09/23
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive CancersGlobeNewsWire • 01/09/23